甲氨蝶呤/蒙脱土插层药物的缓释作用研究  

Study on sustained release effect of Methotrexate/Montmorillonite intercalation drugs

作　　者：安丰田 朱文静 初晓 

机构地区：[1]山东省青岛市立医院药剂科,山东青岛266000

出　　处：《中国现代医学杂志》2017年第29期21-24,共4页China Journal of Modern Medicine

摘　　要：目的研究甲氨蝶呤(MTX)/蒙脱土(MMT)插层药物能否作为临床药物缓释剂。方法采用溶液插层技术制备MTX/MMT缓释体系,利用紫外可见分光光度计、傅立叶红外变换光谱仪等手段进行结构表征,并通过模拟胃、肠液的体外释放实验,来考察缓释体系的释放规律和内在机制。结果在0.8 804μg/ml初始浓度、p H=1、50℃反应4 h时,药物插层量最大。体外释放试验表明,MTX/MMT插层药物在模拟胃、肠液中都有缓释作用,但在模拟胃液中释放量较小、释放速度较慢。结论 MTX/MMT插层药物可以制备成缓释体系,可以作为临床药物缓释剂。Objective To investigate whether Methotrexate/Montmorillonite intercalation drugs （MTX/MMT release system） can be used as drug delivery agents in clinic. Methods MTX/MMT release system was prepared by solution intercalation technique. The experiment adopted UV, FT-IR and other means to characterize the structural characteristics. Through simulation of gastric and intestinal fuid release experiments in vitro, the releasing rules and intrinsic mechanism of sustained-release delivery system were investigated. The initial drug concentration, reaction time, reaction pH value and reaction temperature on the MMT drug loading were explored. Results The maximum amount of drug intercalation was obtained at the initial concentration of 0.8804 μg/ml, pH 1 and 50℃ for 4 hours. In the in vitro release experiment, sustained release of the MTX/MMT release system was observed in the simulated gastric and intestinal fuid, but the amount of release was smaller and the release speed was slower in the simulated gastric fuid. Conclusions Methotrexate/Montmorillonite intercalation drugs may be used as drug delivery agents in clinic.

关 键 词：溶液插层法 蒙脱土 甲氨蝶呤 恒温超声法 紫外分光光度法 

分 类 号：R943[医药卫生—药剂学]